Gossamer Bio (GOSS) reprices multiple stock option grants for COO/CFO
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gossamer Bio, Inc. reported that COO/CFO Bryan Giraudo had several existing stock option awards canceled and reissued as part of a one-time option repricing under the company’s 2019 Incentive Award Plan.
The repricing, effective March 19, 2026, reduced the exercise price of these options to $0.45 per share from prior exercise prices ranging from $0.838 to $2.88, while keeping all other terms, including vesting schedules and option terms, unchanged. These are compensation-related derivative transactions and do not involve open-market purchases or sales of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
22 transactions reported
Mixed
22 txns
Insider
Giraudo Bryan
Role
COO/CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 693,750 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 638,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 543,750 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 181,250 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 211,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 211,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 176,667 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 100,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 60,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 47,667 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 96,667 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 693,750 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 638,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 543,750 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 181,250 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 211,500 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 211,500 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 176,667 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 100,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 60,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 47,667 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 96,667 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
- Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
FAQ
What insider activity did Gossamer Bio (GOSS) report for Bryan Giraudo?
Gossamer Bio reported that COO/CFO Bryan Giraudo had multiple existing stock option grants canceled and reissued on March 19, 2026. The company implemented a one-time repricing, lowering the exercise price on these options while leaving vesting schedules and other terms under the 2019 Incentive Award Plan unchanged.
Did Bryan Giraudo buy or sell Gossamer Bio common stock in this Form 4?
No common stock was bought or sold. The Form 4 shows only derivative transactions in stock options, classified as dispositions to the issuer and grant or award acquisitions. These are compensation-related adjustments and do not represent open-market purchases or sales of Gossamer Bio common shares.
What exercise price were Gossamer Bio options repriced to in this filing?
All affected stock options were repriced to an exercise price of $0.45 per share. Previously, the options carried higher exercise prices ranging from $0.838 to $2.88. The repricing applies to options granted under Gossamer Bio’s 2019 Incentive Award Plan and became effective March 19, 2026.
Were vesting terms changed in Gossamer Bio’s option repricing for Bryan Giraudo?
Vesting terms were not changed. The company states that, apart from reducing the exercise price to $0.45 per share, all other terms and conditions of the repriced options, including vesting provisions and the remaining term, continue in full force under the original award agreements.
What does the Form 4 say about the plan governing Gossamer Bio’s repriced options?
The repriced options were issued under Gossamer Bio’s 2019 Incentive Award Plan. The Form 4 notes that the one-time repricing applied to certain outstanding options granted under this plan, and that the awards continue to vest according to the schedules previously reported in earlier Form 4 filings.
How many types of option transactions are reported for Bryan Giraudo in this Form 4?
The filing reports two types of option transactions: dispositions to the issuer (code D) of existing stock options and grant or award acquisitions (code A) of replacement stock options. Together they represent an option repricing, with no reported exercises, gifts, or tax-withholding transactions.